BioSpace News Archive

Company Reaches Agreement with Regulatory Agency on Key Elements of ENVASARC Trial

Data on final analysis of overall survival (OS) from the Phase III ARAMIS trial investigating NUBEQA® (darolutamide) in men with non-metastatic castration-resistant prostate cancer (nmCRPC)

The LG Chem Life Sciences Innovation Center and LabCentral, today announced a Gold sponsorship agreement including a Golden Ticket which will be awarded to a select startup company in 2020.

Precision Spine, Inc., a medical device company dedicated to Made-in-the-USA manufacturing, introduces the Slimplicity® HP Anterior Cervical Plating (ACP) System, which enables surgeons to accommodate diverse patient anatomies and pathologies with low profile constrained, semi-constrained or hybrid constructs.

ellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious lung diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted its Investigational New Drug (IND) application, allowing the Company to initiate a Phase 3 study of INOpulse® inhaled nitric oxide (iNO) therapy in up to 500 patients infected with COVID-19.

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will appoint Jesper Høiland as Global Chief Commercial Officer upon completion of his transition from Radius Health, Inc. “The addition of Jesper to the senior leadership team at Ascendis Pharma is a key next step in our preparation for the global launch of our

BioDelivery Sciences International, Inc (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey A. Bailey, a member of the Company’s Board of Directors, has been named Interim Chief Executive Officer (CEO), effective today. Mr. Bailey succeeds Herm Cukier as CEO. “On behalf of the Board and our entire Company, I am excited that Jeff

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Kim Sablich as executive vice president, general manager of North America , effective June 1, 2020. In this role, Ms. Sablich will lead Jazz’s newly formed North American regional business structure, including Canada and the U.S., which brings together Medical Affai

Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to improve world health, from Clinical through Commercialization, today unveiled its COVID-19 Risk Mitigation offering, which leverages the company’s significant experience with global viral outbreaks as well as cGMP inspection and CMC review processes to ensure that manufacturers can safely and confidently continue operations through the COVID-19 pandemic.

CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Tiburio Therapeutics Inc., a clinical stage company developing therapies for rare endocrine diseases, today published new data from a preclinical study in the Journal of the Endocrine Society demonstrating that its lead clinical asset, TBR-760, a dopamine somatostatin chimeric compound, arrests aggressive non-functioning pituitary adenoma (NFPA) growth in a mouse model. The pre-clinical data indicate that TBR-760 completely arrested tumor gr